Suggested remit - To appraise the clinical and cost effectiveness of LentiGlobin within its marketing authorisation for treating transfusion-dependant beta-thalassaemia
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
968
|
Provisional Schedule
| Committee meeting |
06 May 2020 |
| Expected publication |
15 July 2020 |
Project Team
Email enquiries
| Evidence Review Group / Assessment Group |
Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Consultees
| Companies sponsors |
bluebird bio (Zynteglo) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
UK Thalassaemia Society |
| Professional groups |
British Society for Haematology |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
Commentators
| Comparator companies |
Novartis Pharmaceuticals (desferrioxamine, deferasirox) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cell and Gene Therapy Catapult |
|
Date
|
Update
|
|
01 August 2019
|
Invitation to participate |
|
01 August 2019
|
In progress, Invitation to participate |
|
14 June 2019 - 12 July 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
15 April 2019
|
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lentiGlobin within its anticipated marketing authorisation for treating transfusion-dependent beta-thalassaemia.
The appraisal is expected to start in approximately early August 2019 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early October 2019.
These timings are based on a request from the company to reschedule the initial date set by NICE until after the anticipated marketing authorisation has been received, enabling additional evidence to be considered and to align with when the company hopes to launch the product in England and Wales. |
|
16 May 2018 (10:00)
|
Scoping workshop (London) |
|
21 March 2018 - 20 April 2018
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance